What is sclerosing epithelioid fibrosarcoma?
Sclerosing epithelioid fibrosarcoma (SEF) is a rare soft-tissue sarcoma, a cancer of the body’s connective tissue. It usually starts deep in the muscles or fibrous tissue of the thigh, trunk, shoulder or pelvis, and occasionally in bone or internal organs.
Its name describes how it looks under the microscope. The tumour cells are epithelioid (rounded, like lining cells), and they sit in cords and nests within very dense, scar-like collagen, a feature called sclerosis.
SEF was first recognised as a separate tumour in the 1990s. It is now regarded as a close relative of low-grade fibromyxoid sarcoma (LGFMS), and some tumours show features of both. Both types share a marker protein, MUC4, and similar gene fusions (Doyle et al., 2012).
Although SEF often grows slowly and may look harmless at first, it is an aggressive sarcoma. It tends to come back after surgery and to spread, especially to the lungs, bones and pleura, sometimes many years later (Warmke, Yu and Meis, 2024).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Fibroblastic soft-tissue sarcoma |
| How common | Very rare; a few hundred cases reported worldwide |
| Typical age | Adults, median about 45-50 years; children and older people occasionally |
| Sex | Men and women affected about equally |
| Common sites | Deep soft tissue of the thigh, buttock, trunk, shoulder and neck; sometimes bone, kidney or other organs |
| Key marker | MUC4 protein |
| Usual gene change | EWSR1::CREB3L1 fusion; FUS::CREB3L2 in hybrid tumours |
| Main treatment | Wide surgical removal, often with radiotherapy |
| Outlook | Guarded; recurrence and spread are common |
2. Causes and risk factors
The cause of SEF is not known. It is not linked to injury, lifestyle or diet, and there is no known inherited form.
Gene changes
| Gene change | Where it is found | Notes |
|---|---|---|
| EWSR1::CREB3L1 | The most common change in pure SEF | Joins two genes to create an abnormal growth signal |
| FUS::CREB3L2 | Hybrid SEF-LGFMS tumours and LGFMS | The same fusion found in low-grade fibromyxoid sarcoma |
| Other EWSR1 or FUS fusions | A minority | Partners such as CREB3L2 or CREB3L3 |
| YAP1::KMT2A | A distinct subgroup, often in bone or with unusual features | Described in a small number of tumours (Murshed, Al-Bozom and Ammar, 2021) |
These gene changes are found only in the tumour cells. They are not inherited and cannot be passed on.
SEF and low-grade fibromyxoid sarcoma
| Feature | SEF | LGFMS |
|---|---|---|
| Main cell type | Epithelioid cells in dense collagen | Bland spindle cells in fibrous and myxoid tissue |
| MUC4 staining | Positive in most | Positive in almost all |
| Usual fusion | EWSR1::CREB3L1 | FUS::CREB3L2 |
| Behaviour | Aggressive; metastases common | Slow, but late relapse is common |
| Hybrid tumours | Share features of both |
3. How does it look
To the patient
SEF usually feels like a firm, deep lump that has been present for months or even years. It is often painless at first and can be mistaken for a harmless swelling or a pulled muscle.
During surgery
| Feature | Description |
|---|---|
| Shape | A rounded or lobulated mass, often with a fairly well-defined edge |
| Size | Commonly 5-10 cm, but from 2 cm to over 20 cm |
| Cut surface | Firm, white-grey and gritty, like scar tissue |
| Hidden extension | Small finger-like spurs into nearby muscle, fat or bone |
| Bleeding or cysts | Uncommon |
On scans
On MRI, SEF is often dark on many sequences because of its dense collagen, with patchy enhancement after contrast. CT may show erosion of nearby bone. The appearance is not specific, so a biopsy is always needed.
Under the microscope
| Feature | Description |
|---|---|
| Cells | Small to medium round cells with clear or pale pink cytoplasm |
| Pattern | Cords, single-file lines, nests and small sheets |
| Background | Very dense, hyalinised (glassy) collagen |
| Mitoses | Often few, which can make the tumour look deceptively bland |
| Stains | MUC4 strongly positive in most; usually negative for keratin, S100 and muscle markers |
| Molecular test | FISH or sequencing to find EWSR1 or FUS rearrangements |
Conditions that can look similar
SEF can be mistaken for metastatic carcinoma, lymphoma, sclerosing epithelioid variants of other sarcomas, ossifying fibromyxoid tumour and even scar tissue. Because the tumour is so rare, a specialist sarcoma pathologist should confirm the diagnosis (Warmke, Yu and Meis, 2024).
4. Symptoms
Common symptoms
- A firm, deep lump, usually in the limbs, trunk or girdle areas
- A lump that has slowly grown over months or years
- Pain or tenderness in about a third of people, often as the lump enlarges
- Stiffness or reduced movement near a joint
- Numbness or tingling if the tumour presses on a nerve
Symptoms by site
| Site | Possible symptoms |
|---|---|
| Thigh, buttock or pelvis | Deep ache, limp, swelling |
| Shoulder or chest wall | Pain on movement, visible swelling |
| Head and neck | A lump in the neck or jaw region |
| Bone | Bone pain, fracture after minor injury |
| Kidney or other organs | Pain, blood in the urine, or no symptoms until large |
Symptoms of spread
| Site of spread | Possible symptoms |
|---|---|
| Lungs | Cough, breathlessness, chest pain |
| Pleura | Fluid around the lung, breathlessness |
| Bone | Bone pain, fracture |
| Lymph nodes | Swollen glands |
| General | Tiredness, weight loss |
When to seek medical advice
See a doctor about any lump that is larger than about 5 cm, deep in the muscle, growing or painful. Most lumps are harmless, but these features should lead to an ultrasound or MRI and, if needed, referral to a sarcoma centre.
5. Diagnosis
| Test | Purpose |
|---|---|
| Ultrasound | First check of a lump |
| MRI | Shows the size, depth and relation to nerves, vessels and bone |
| Core needle biopsy | Taken at a sarcoma centre, along the planned surgical route |
| Immunohistochemistry | MUC4 and other stains |
| Molecular testing | Confirms an EWSR1, FUS or other fusion |
| CT of the chest | Looks for lung spread |
| PET-CT or bone scan | Sometimes used to check for spread to bone |
Why diagnosis can be delayed
- The lump often grows slowly and causes little pain
- Small biopsies may show mainly collagen, which looks like scar
- The cells may look bland, hiding how aggressive the tumour is
- The tumour is rare, so many doctors and pathologists never see one
Staging
Like other soft-tissue sarcomas, SEF is staged using the size of the tumour, whether it has reached lymph nodes, and whether it has spread to distant organs. The grade given by the usual sarcoma grading system can be misleading in SEF, because the bland-looking cells may score as low grade even though the tumour behaves aggressively.
| Stage group | Meaning in simple terms |
|---|---|
| Localised | The tumour is confined to one area and can usually be removed |
| Locally advanced | The tumour involves nerves, major vessels or bone, making surgery more complex |
| Metastatic | The tumour has spread, most often to the lungs, pleura or bone |
6. Treatment
Treatment should be planned at a specialist sarcoma centre by a multidisciplinary team.
Surgery
| Approach | Notes |
|---|---|
| Wide local excision | The main treatment; removes the tumour with a margin of normal tissue |
| Limb-sparing surgery | Preferred in the arms and legs whenever possible |
| Reconstruction | Muscle flaps, grafts or bone reconstruction for large defects |
| Removal of lung metastases | Considered for a small number of lung nodules |
Radiotherapy
Radiotherapy can be used ahead of the operation or afterwards to lower the risk of local recurrence, especially when the margins are close. It is also used to relieve pain from metastases.
Drug treatment
| Option | Notes |
|---|---|
| Doxorubicin-based chemotherapy | Standard first option for advanced sarcoma; SEF responds poorly in many reports |
| Ifosfamide, gemcitabine, docetaxel or trabectedin | Used in later lines with modest benefit |
| Pazopanib and other targeted drugs | Occasional disease control reported |
| Clinical trials | Strongly encouraged, as no drug is known to work reliably |
Treatment if SEF comes back or spreads
When SEF returns at the original site, a second operation, sometimes with radiotherapy, can often control it again. When it spreads, the aim is usually to control growth and symptoms for as long as possible:
- Surgery or precise radiotherapy (stereotactic treatment) for a few slowly growing metastases
- Drug treatment when there are many metastases or rapid growth
- Watchful waiting with regular scans when metastases are small and stable, to avoid side effects until treatment is needed
- Palliative care to manage pain, breathlessness and tiredness alongside other treatment
Side effects
| Treatment | Possible side effects |
|---|---|
| Surgery | Pain, wound problems, weakness, swelling of a limb |
| Radiotherapy | Skin soreness, tiredness, later stiffness and scarring |
| Chemotherapy | Hair loss, sickness, low blood counts, tiredness, heart effects (doxorubicin) |
| Targeted drugs | Diarrhoea, high blood pressure, liver changes, change in hair colour |
What treatment involves day to day
| Part of treatment | What to expect |
|---|---|
| Sarcoma surgery | Hospital stay of a few days to two weeks |
| Rehabilitation | Physiotherapy for weeks or months after limb surgery |
| Radiotherapy | Daily sessions on weekdays for about 5-6 weeks |
| Chemotherapy | Treatment every 3 weeks, sometimes with short hospital stays |
7. Outlook (prognosis)
SEF is regarded as a high-risk sarcoma, even when the cells look bland.
| Measure | Approximate figures from published series |
|---|---|
| Local recurrence | About half of patients |
| Distant spread | Roughly 50-80% at some point, often to lungs, bone and pleura |
| Spread present at diagnosis | A significant minority |
| Late relapse | Can occur more than 10 years after surgery |
Pure SEF behaves more aggressively than hybrid SEF-LGFMS tumours or LGFMS itself (Antonescu et al., 2001; Warmke, Yu and Meis, 2024). Complete removal, smaller size and absence of spread at diagnosis are linked with better results. Some people live for many years with slowly growing metastases.
Research and future treatments
Because SEF is driven by a single gene fusion in most cases, researchers are studying how the abnormal CREB3L1 protein drives tumour growth and whether it can be blocked. Laboratory models made from patients’ tumours are helping to test new drug combinations (Woods et al., 2021). International sarcoma groups are also pooling cases so that treatment results can be compared across many centres.
8. Follow-up
| Follow-up | Purpose |
|---|---|
| Clinic visits every 3-6 months at first | Examination of the scar and surrounding area |
| MRI of the original site | Detects local recurrence |
| CT of the chest | Detects lung spread |
| Long-term follow-up for 10 years or more | Because late relapse is typical |
9. Living with sclerosing epithelioid fibrosarcoma
- Keep a long-term follow-up plan, even after many years without problems
- Report any new lump, pain or cough without waiting for the next appointment
- Continue physiotherapy to keep strength and movement after surgery
- Ask about lymphoedema care if a limb swells after treatment
- Ask about clinical trials for rare sarcomas
- Seek support from sarcoma charities, specialist nurses and patient groups
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is SEF the same as fibrosarcoma? | No. It is a distinct sarcoma with its own markers and gene changes |
| Is it inherited? | No |
| Why do the doctors call it aggressive when it grew so slowly? | Despite slow growth, SEF often comes back and spreads over time |
| Will I need chemotherapy? | Not usually for localised disease; it is mainly used if the cancer spreads |
| How long will I be followed up? | Usually for at least 10 years |
| Can children get SEF? | Rarely, yes |
11. Questions to ask your care team
- Is this pure SEF or a hybrid with LGFMS?
- Which gene fusion does my tumour have?
- Were the margins clear after surgery?
- Do I need radiotherapy?
- How often will I have scans, and of which areas?
- Are there clinical trials I could join?
Resources
- Antonescu, C.R. et al. (2001) ‘Sclerosing epithelioid fibrosarcoma: a study of 16 cases and confirmation of a clinicopathologically distinct tumor’, American Journal of Surgical Pathology, 25(6), pp. 699-709.
- Doyle, L.A. et al. (2012) ‘MUC4 is a sensitive and extremely useful marker for sclerosing epithelioid fibrosarcoma: association with FUS gene rearrangement’, American Journal of Surgical Pathology, 36(10), pp. 1444-1451.
- Murshed, K.A., Al-Bozom, I. and Ammar, A. (2021) ‘Sclerosing epithelioid fibrosarcoma: in-depth review of a genetically heterogeneous tumor’, APMIS, 129(8), pp. 455-460.
- Warmke, L.M., Yu, W. and Meis, J.M. (2024) ‘Sclerosing epithelioid fibrosarcoma’, Surgical Pathology Clinics, 17(1), pp. 119-139.
- Woods, A.D. et al. (2021) ‘Metastatic pediatric sclerosing epithelioid fibrosarcoma’, Cold Spring Harbor Molecular Case Studies, 7(5), a006093.
- National Cancer Institute (2026) Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.